SML2543
KA-11
≥98% (HPLC)
别名:
1-[1-Methyl-2-oxo-2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2,5-pyrrolidinedione
InChI
1S/C18H20F3N3O3/c1-12(24-15(25)5-6-16(24)26)17(27)23-9-7-22(8-10-23)14-4-2-3-13(11-14)18(19,20)21/h2-4,11-12H,5-10H2,1H3
InChI key
DWLZEEPJISTVEO-UHFFFAOYSA-N
SMILES string
CC(N1C(CCC1=O)=O)C(N(CC2)CCN2C3=CC=CC(C(F)(F)F)=C3)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Broad-spectrum anticonvulsant
KA-11 is a broad-spectrum anticonvulsant hybrid molecule that joins the chemical fragments of well-known anti-epileptic drugs such as ethosuximide, levetiracetam, and lacosamide. KA-11 was shown to have antiepileptogenic and antinociceptive properties in animal models. Its mechanism of action is believed to involve influence on the neuronal voltage-sensitive sodium and L-type calcium channels.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Katarzyna Socała et al.
ACS chemical neuroscience, 10(1), 636-648 (2018-09-25)
Recently, compound KA-11 was identified as a promising candidate for a new broad-spectrum anticonvulsant. This compound revealed wide protective activity across the most important animal models of seizures such as the maximal electroshock test (MES), the subcutaneous pentylenetetrazole test (
Krzysztof Kamiński et al.
Journal of medicinal chemistry, 58(13), 5274-5286 (2015-06-09)
The library of 27 new 1-(4-phenylpiperazin-1-yl)- or 1-(morpholin-4-yl)-(2,5-dioxopyrrolidin-1-yl)propanamides and (2,5-dioxopyrrolidin-1-yl)butanamides as potential new hybrid anticonvulsant agents was synthesized. These hybrid molecules join the chemical fragments of well-known antiepileptic drugs (AEDs) such as ethosuximide, levetiracetam, and lacosamide. Compounds 5, 10, 11
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持